Trial Profile
Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2019
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms STONE
- Sponsors Chengdu Kanghong Biotech
- 20 Feb 2017 New trial record